{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:32:37Z","timestamp":1790609557883,"version":"4.1.0"},"reference-count":236,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI141333"],"award-info":[{"award-number":["R01 AI141333"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA196589"],"award-info":[{"award-number":["T32-CA196589"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007890","name":"UNC | University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","award":["23-01"],"award-info":[{"award-number":["23-01"]}],"id":[{"id":"10.13039\/100007890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Seasonal influenza and the current COVID-19 pandemic represent looming global health challenges. Efficacious and safe vaccines remain the frontline tools for mitigating both influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u2013induced diseases. This review will discuss the existing strategies for influenza vaccines and how these strategies have informed SARS-CoV-2 vaccines. It will also discuss new vaccine platforms and potential challenges for both viruses.<\/jats:p>","DOI":"10.4049\/jimmunol.2001287","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T14:55:16Z","timestamp":1621608916000},"page":"2509-2520","source":"Crossref","is-referenced-by-count":22,"title":["Influenza Virus and SARS-CoV-2 Vaccines"],"prefix":"10.1093","volume":"206","author":[{"given":"Adam M","family":"Sandor","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Department of Genetics, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-2275","authenticated-orcid":false,"given":"Michael S","family":"Sturdivant","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Biological and Biomedical Sciences Program, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7846-0395","authenticated-orcid":false,"given":"Jenny P Y","family":"Ting","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Department of Genetics, University of North Carolina at Chapel Hill , Chapel Hill, NC"},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill , Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"key":"2025030417503669900_r1","article-title":"Pandemic influenza risk management: a WHO guide to inform and harmonize national and international pandemic preparedness and response","author":"World Health Organization","year":"2017"},{"key":"2025030417503669900_r2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra1208802","article-title":"Pandemic preparedness and response--lessons from the H1N1 influenza of 2009","volume":"370","author":"Fineberg","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r3","doi-asserted-by":"crossref","first-page":"a038489","DOI":"10.1101\/cshperspect.a038489","article-title":"The ecology and evolution of influenza viruses","volume":"10","author":"Wille","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2025030417503669900_r4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrmicro.2017.146","article-title":"The evolution of seasonal influenza viruses. [Published erratum appears in 2018 Nat. Rev. Microbiol. 16: 47\u201360.]","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"2025030417503669900_r5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/mr.56.1.152-179.1992","article-title":"Evolution and ecology of influenza A viruses","volume":"56","author":"Webster","year":"1992","journal-title":"Microbiol. Rev."},{"key":"2025030417503669900_r6","doi-asserted-by":"crossref","first-page":"e1006685","DOI":"10.1371\/journal.ppat.1006685","article-title":"Fitness cost of reassortment in human influenza","volume":"13","author":"Villa","year":"2017","journal-title":"PLoS Pathog."},{"key":"2025030417503669900_r7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrg2053","article-title":"The evolution of epidemic influenza","volume":"8","author":"Nelson","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"2025030417503669900_r8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMp038238","article-title":"Influenza vaccine--outmaneuvering antigenic shift and drift","volume":"350","author":"Treanor","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/irv.12412","article-title":"The ecology and adaptive evolution of influenza A interspecies transmission","volume":"11","author":"Joseph","year":"2017","journal-title":"Influenza Other Respir. Viruses"},{"key":"2025030417503669900_r10","doi-asserted-by":"crossref","first-page":"e27512","DOI":"10.1371\/journal.pone.0027512","article-title":"Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"2025030417503669900_r11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrmicro1208","article-title":"Influenza: lessons from past pandemics, warnings from current incidents","volume":"3","author":"Horimoto","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"2025030417503669900_r12","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1038\/nm1141","article-title":"Influenza: old and new threats","volume":"10","author":"Palese","year":"2004","journal-title":"Nat. Med."},{"key":"2025030417503669900_r13","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1126\/science.275.5307.1793","article-title":"Initial genetic characterization of the 1918 \u201cSpanish\u201d influenza virus","volume":"275","author":"Taubenberger","year":"1997","journal-title":"Science"},{"key":"2025030417503669900_r14","article-title":"Up to 650 000 people die of respiratory diseases linked to seasonal flu each year","author":"World Health Organization","year":"2017"},{"key":"2025030417503669900_r15","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1093\/cid\/ciz1244","article-title":"Effects of influenza vaccination in the United States during the 2018-2019 influenza season","volume":"71","author":"Chung","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2025030417503669900_r16","first-page":"161","article-title":"Influenza vaccine for 2019-2020","volume":"61","year":"2019","journal-title":"Med. Lett. Drugs Ther."},{"key":"2025030417503669900_r17","article-title":"CDC Seasonal Flu Vaccine Effectiveness Studies","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2025030417503669900_r18","doi-asserted-by":"crossref","first-page":"20390","DOI":"10.2807\/ese.18.05.20390-en","article-title":"Low and decreasing vaccine effectiveness against influenza A(H3) in 2011\/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study","volume":"18","author":"Kissling","year":"2013","journal-title":"Eurosurveillance"},{"key":"2025030417503669900_r19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/irv.12570","article-title":"65 years of influenza surveillance by a World Health Organization-coordinated global network","volume":"12","author":"Ziegler","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"2025030417503669900_r20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.vaccine.2017.01.018","article-title":"Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015","volume":"35","author":"Hampson","year":"2017","journal-title":"Vaccine"},{"key":"2025030417503669900_r21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r22","article-title":"WHO recommendations on the composition of influenza virus vaccines","author":"World Health Organization","year":"2020"},{"key":"2025030417503669900_r23","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1080\/21645515.2017.1313375","article-title":"A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control","volume":"13","author":"Ray","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025030417503669900_r24","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm1210-1389","article-title":"Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine","volume":"16","author":"Nabel","year":"2010","journal-title":"Nat. Med."},{"key":"2025030417503669900_r25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/nyas.12462","article-title":"Continuing challenges in influenza","volume":"1323","author":"Webster","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030417503669900_r26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.1218888","article-title":"Seroevidence for H5N1 influenza infections in humans: meta-analysis","volume":"335","author":"Wang","year":"2012","journal-title":"Science"},{"key":"2025030417503669900_r27","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"2025030417503669900_r28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature10831","article-title":"Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA\/H1N1 virus in ferrets","volume":"486","author":"Imai","year":"2012","journal-title":"Nature"},{"key":"2025030417503669900_r29","article-title":"How influenza (flu) vaccines are made","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2025030417503669900_r30","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1016\/j.vaccine.2017.08.034","article-title":"The road to a more effective influenza vaccine: up to date studies and future prospects","volume":"35","author":"Sano","year":"2017","journal-title":"Vaccine"},{"key":"2025030417503669900_r31","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"2025030417503669900_r32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4049\/immunohorizons.1900022","article-title":"Chimeric hemagglutinin-based influenza virus vaccines induce protective stalk-specific humoral immunity and cellular responses in mice","volume":"3","author":"Choi","year":"2019","journal-title":"Immunohorizons"},{"key":"2025030417503669900_r33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41541-019-0126-4","article-title":"A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains","volume":"4","author":"Broecker","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2025030417503669900_r34","doi-asserted-by":"crossref","first-page":"a029413","DOI":"10.1101\/cshperspect.a029413","article-title":"Is it possible to develop a \u201cuniversal\u201d influenza virus vaccine? immunogenetic considerations underlying B-cell biology in the development of a pan-subtype influenza A vaccine targeting the hemagglutinin stem","volume":"10","author":"Andrews","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2025030417503669900_r35","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI122895","article-title":"Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance","volume":"128","author":"Liu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"2025030417503669900_r36","doi-asserted-by":"crossref","first-page":"14234","DOI":"10.1038\/ncomms14234","article-title":"A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action. [Published erratum appears in 2017 Nat. Commun. 8: 15779.]","volume":"8","author":"Chai","year":"2017","journal-title":"Nat. Commun."},{"key":"2025030417503669900_r37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"2025030417503669900_r38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2016.06.043","article-title":"Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses","volume":"166","author":"Joyce","year":"2016","journal-title":"Cell"},{"key":"2025030417503669900_r39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/prot.24745","article-title":"Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage","volume":"83","author":"Xu","year":"2015","journal-title":"Proteins"},{"key":"2025030417503669900_r40","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1038\/ncomms8708","article-title":"A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus","volume":"6","author":"Wu","year":"2015","journal-title":"Nat. Commun."},{"key":"2025030417503669900_r41","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/ncomms4614","article-title":"Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus","volume":"5","author":"Lee","year":"2014","journal-title":"Nat. Commun."},{"key":"2025030417503669900_r42","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1128\/JVI.00178-14","article-title":"Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody","volume":"88","author":"Wyrzucki","year":"2014","journal-title":"J. Virol."},{"key":"2025030417503669900_r43","doi-asserted-by":"crossref","first-page":"200fs34","DOI":"10.1126\/scitranslmed.3007118","article-title":"Universal flu vaccines: primum non nocere","volume":"5","author":"Crowe","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2025030417503669900_r44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1073\/pnas.1218256109","article-title":"Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody","volume":"110","author":"Schmidt","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417503669900_r45","doi-asserted-by":"crossref","first-page":"e1003150","DOI":"10.1371\/journal.ppat.1003150","article-title":"Human monoclonal antibodies broadly neutralizing against influenza B virus","volume":"9","author":"Yasugi","year":"2013","journal-title":"PLoS Pathog."},{"key":"2025030417503669900_r46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.virol.2012.09.034","article-title":"Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient","volume":"435","author":"Hu","year":"2013","journal-title":"Virology"},{"key":"2025030417503669900_r47","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1016\/j.vaccine.2012.06.086","article-title":"Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response","volume":"30","author":"Taylor","year":"2012","journal-title":"Vaccine"},{"key":"2025030417503669900_r48","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nature11414","article-title":"Cross-neutralization of influenza A viruses mediated by a single antibody loop","volume":"489","author":"Ekiert","year":"2012","journal-title":"Nature"},{"key":"2025030417503669900_r49","doi-asserted-by":"crossref","first-page":"e34415","DOI":"10.1371\/journal.pone.0034415","article-title":"A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses","volume":"7","author":"De Marco","year":"2012","journal-title":"PLoS One"},{"key":"2025030417503669900_r50","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1128\/JVI.05397-11","article-title":"Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5","volume":"85","author":"Ohshima","year":"2011","journal-title":"J. Virol."},{"key":"2025030417503669900_r51","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1128\/JVI.00700-11","article-title":"A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin","volume":"85","author":"Krause","year":"2011","journal-title":"J. Virol."},{"key":"2025030417503669900_r52","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"2025030417503669900_r53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1204839","article-title":"A highly conserved neutralizing epitope on group 2 influenza A viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"2025030417503669900_r54","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"Whittle","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417503669900_r55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J. Exp. Med."},{"key":"2025030417503669900_r56","doi-asserted-by":"crossref","first-page":"e1000990","DOI":"10.1371\/journal.ppat.1000990","article-title":"Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries","volume":"6","author":"Kashyap","year":"2010","journal-title":"PLoS Pathog."},{"key":"2025030417503669900_r57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.12.014","article-title":"Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV)","volume":"399","author":"Burioni","year":"2010","journal-title":"Virology"},{"key":"2025030417503669900_r58","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1073\/pnas.0801367105","article-title":"Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies","volume":"105","author":"Kashyap","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417503669900_r59","doi-asserted-by":"crossref","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PLoS One"},{"key":"2025030417503669900_r60","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1128\/jvi.67.5.2552-2558.1993","article-title":"A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains","volume":"67","author":"Okuno","year":"1993","journal-title":"J. Virol."},{"key":"2025030417503669900_r61","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/infdis\/jiy103","article-title":"A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases","volume":"218","author":"Erbelding","year":"2018","journal-title":"J. Infect. Dis."},{"key":"2025030417503669900_r62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMp1714916","article-title":"Chasing seasonal influenza - the need for a universal influenza vaccine","volume":"378","author":"Paules","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r63","doi-asserted-by":"crossref","first-page":"1459394","DOI":"10.1155\/2016\/1459394","article-title":"Adjuvants: classification, modus operandi, and licensing","volume":"2016","author":"Apost\u00f3lico","year":"2016","journal-title":"J. Immunol. Res."},{"key":"2025030417503669900_r64","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1084\/jem.20071087","article-title":"Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells","volume":"205","author":"Kool","year":"2008","journal-title":"J. Exp. Med."},{"key":"2025030417503669900_r65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4049\/jimmunol.181.1.17","article-title":"Cutting edge: inflammasome activation by alum and alum\u2019s adjuvant effect are mediated by NLRP3","volume":"181","author":"Li","year":"2008","journal-title":"J. Immunol."},{"key":"2025030417503669900_r66","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1080\/21645515.2017.1415684","article-title":"Adjuvanted influenza vaccines","volume":"14","author":"Tregoning","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025030417503669900_r67","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1073\/pnas.1519690113","article-title":"Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood","volume":"113","author":"Nakaya","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417503669900_r68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59\u00ae adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"2025030417503669900_r69","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine"},{"key":"2025030417503669900_r70","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"2025030417503669900_r71","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1073\/pnas.1107941108","article-title":"Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88","volume":"108","author":"Seubert","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417503669900_r72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"2025030417503669900_r73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2017.11.030","article-title":"A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination","volume":"270","author":"Junkins","year":"2018","journal-title":"J. Control. Release"},{"key":"2025030417503669900_r74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jconrel.2018.09.020","article-title":"Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy","volume":"289","author":"Chen","year":"2018","journal-title":"J. Control. Release"},{"key":"2025030417503669900_r75","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/2211738506666180918122337","article-title":"Drug delivery for cancer immunotherapy and vaccines","volume":"6","author":"Batty","year":"2018","journal-title":"Pharm. Nanotechnol."},{"issue":"1","key":"2025030417503669900_r76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.imlet.2014.07.004","article-title":"Targeting human dendritic cells in situ to improve vaccines","volume":"162","author":"Sehgal","year":"2014","journal-title":"Immunol. Lett."},{"key":"2025030417503669900_r77","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2217\/nnm.14.135","article-title":"Development of functionalized nanoparticles for vaccine delivery to dendritic cells: a mechanistic approach","volume":"9","author":"Silva","year":"2014","journal-title":"Nanomedicine (Lond.)"},{"key":"2025030417503669900_r78","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cbpa.2013.06.013","article-title":"New generation of oral mucosal vaccines targeting dendritic cells","volume":"17","author":"Owen","year":"2013","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2025030417503669900_r79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2012.11.015","article-title":"Nanogel vaccines targeting dendritic cells: contributions of the surface decoration and vaccine cargo on cell targeting and activation","volume":"166","author":"Thomann-Harwood","year":"2013","journal-title":"J. Control. Release"},{"key":"2025030417503669900_r80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.colsurfb.2013.04.007","article-title":"Facile fabrication of uniform size-controlled microparticles and potentiality for tandem drug delivery system of micro\/nanoparticles","volume":"109","author":"Iwanaga","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"2025030417503669900_r81","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/mp300643d","article-title":"Efficient delivery of the toll-like receptor agonists polyinosinic:polycytidylic acid and CpG to macrophages by acetalated dextran microparticles","volume":"10","author":"Peine","year":"2013","journal-title":"Mol. Pharm."},{"key":"2025030417503669900_r82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"2025030417503669900_r83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.addr.2011.01.012","article-title":"Nanoparticles and microparticles for skin drug delivery","volume":"63","author":"Prow","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2025030417503669900_r84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bit.21301","article-title":"Microparticles and nanoparticles for drug delivery","volume":"96","author":"Kohane","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"2025030417503669900_r85","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/CJI.0b013e31802cf3e3","article-title":"\u201cPathogen-mimicking\u201d nanoparticles for vaccine delivery to dendritic cells","volume":"30","author":"Elamanchili","year":"2007","journal-title":"J. Immunother."},{"key":"2025030417503669900_r86","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.it.2006.10.005","article-title":"Targeting dendritic cells with biomaterials: developing the next generation of vaccines","volume":"27","author":"Reddy","year":"2006","journal-title":"Trends Immunol."},{"key":"2025030417503669900_r87","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/A:1014474414097","article-title":"Targeting vaccines to dendritic cells","volume":"19","author":"Foged","year":"2002","journal-title":"Pharm. Res."},{"key":"2025030417503669900_r88","first-page":"503","article-title":"Nanoparticles and microparticles for drug and vaccine delivery","volume":"189","author":"Kreuter","year":"1996","journal-title":"J. Anat."},{"key":"2025030417503669900_r89","doi-asserted-by":"crossref","first-page":"eaau0810","DOI":"10.1126\/science.aau0810","article-title":"Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity","volume":"367","author":"Wang","year":"2020","journal-title":"Science"},{"key":"2025030417503669900_r90","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1021\/acs.molpharmaceut.8b00579","article-title":"Acetalated dextran microparticles for codelivery of STING and TLR7\/8 agonists","volume":"15","author":"Collier","year":"2018","journal-title":"Mol. Pharm."},{"key":"2025030417503669900_r91","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.3389\/fimmu.2018.02874","article-title":"Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?","volume":"9","author":"Ho","year":"2018","journal-title":"Front. Immunol."},{"key":"2025030417503669900_r92","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1021\/mp900311x","article-title":"In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants","volume":"7","author":"Bachelder","year":"2010","journal-title":"Mol. Pharm."},{"key":"2025030417503669900_r93","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1440-1711.2005.01315.x","article-title":"Lipid based particulate formulations for the delivery of antigen","volume":"83","author":"Copland","year":"2005","journal-title":"Immunol. Cell Biol."},{"key":"2025030417503669900_r94","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.vaccine.2016.11.013","article-title":"Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis","volume":"35","author":"Young","year":"2017","journal-title":"Vaccine"},{"key":"2025030417503669900_r95","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2010.03.067","article-title":"Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence","volume":"28","author":"Song","year":"2010","journal-title":"Vaccine"},{"key":"2025030417503669900_r96","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","article-title":"Neutralization and antibody-dependent enhancement of dengue viruses","volume":"60","author":"Halstead","year":"2003","journal-title":"Adv. Virus Res."},{"key":"2025030417503669900_r97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications","volume":"13","author":"Takada","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"2025030417503669900_r98","doi-asserted-by":"crossref","first-page":"200ra114","DOI":"10.1126\/scitranslmed.3006366","article-title":"Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease","volume":"5","author":"Khurana","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2025030417503669900_r99","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/aje\/kwt051","article-title":"Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010","volume":"178","author":"Polakowski","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"2025030417503669900_r101","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40264-015-0350-4","article-title":"Comparative safety of vaccine adjuvants: a summary of current evidence and future needs","volume":"38","author":"Petrovsky","year":"2015","journal-title":"Drug Saf."},{"key":"2025030417503669900_r102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis. [Published erratum appears in 2020 J. Med. Virol. 92: 2249.]","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"2025030417503669900_r104","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2025030417503669900_r105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r106","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time. [Published erratum appears in 2020 Lancet Infect Dis. 20: e215.]","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3934\/publichealth.2021011","article-title":"A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19","volume":"8","author":"Umakanthan","year":"2021","journal-title":"AIMS Public Health"},{"key":"2025030417503669900_r108","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/pathogens9060426","article-title":"A review on SARS-CoV-2 virology, pathophysiology, animal models, and anti-viral interventions","volume":"9","author":"Neerukonda","year":"2020","journal-title":"Pathogens"},{"key":"2025030417503669900_r109","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.cell.2020.05.041","article-title":"Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19","volume":"181","author":"Sempowski","year":"2020","journal-title":"Cell."},{"key":"2025030417503669900_r110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2025030417503669900_r111","article-title":"DRAFT landscape of COVID-19 candidate vaccines \u2013 October 19, 2020","author":"World Health Organization","year":"2020"},{"key":"2025030417503669900_r112","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"2025030417503669900_r113","doi-asserted-by":"crossref","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","article-title":"Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice in mice","volume":"32","author":"Pruijssers","year":"2020","journal-title":"Cell. Rep."},{"key":"2025030417503669900_r114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"2025030417503669900_r115","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrmicro3143","article-title":"A decade after SARS: strategies for controlling emerging coronaviruses","volume":"11","author":"Graham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"2025030417503669900_r116","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"2025030417503669900_r117","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(03)13413-7","article-title":"Lung pathology of fatal severe acute respiratory syndrome","volume":"361","author":"Nicholls","year":"2003","journal-title":"Lancet"},{"key":"2025030417503669900_r118","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/path.1440","article-title":"The clinical pathology of severe acute respiratory syndrome (SARS): a report from China","volume":"200","author":"Ding","year":"2003","journal-title":"J. Pathol."},{"key":"2025030417503669900_r119","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"2025030417503669900_r120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.micinf.2013.06.003","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread","volume":"15","author":"Lu","year":"2013","journal-title":"Microbes Infect."},{"key":"2025030417503669900_r121","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMe2009758","article-title":"Asymptomatic transmission, the Achilles\u2019 heel of current strategies to control Covid-19","volume":"382","author":"Gandhi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r122","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(04)16255-7","article-title":"Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome","volume":"363","author":"Cheng","year":"2004","journal-title":"Lancet"},{"key":"2025030417503669900_r123","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019. [Published erratum appears in 2020 Nature 588: E35.]","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"2025030417503669900_r124","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r126","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r127","doi-asserted-by":"crossref","first-page":"198043","DOI":"10.1016\/j.virusres.2020.198043","article-title":"Clinical features of familial clustering in patients infected with 2019 novel coronavirus in Wuhan, China","volume":"286","author":"Li","year":"2020","journal-title":"Virus Res."},{"key":"2025030417503669900_r128","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"2025030417503669900_r129","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1515\/cclm-2020-0188","article-title":"Prominent changes in blood coagulation of patients with SARS-CoV-2 infection","volume":"58","author":"Han","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"2025030417503669900_r130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","article-title":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","volume":"77","author":"Mao","year":"2020","journal-title":"JAMA Neurol."},{"key":"2025030417503669900_r131","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/j.gastro.2020.04.008","article-title":"High prevalence of concurrent gastrointestinal manifestations in patients with severe acute respiratory syndrome coronavirus 2: early experience from California","volume":"159","author":"Cholankeril","year":"2020","journal-title":"Gastroenterology"},{"key":"2025030417503669900_r132","first-page":"1","article-title":"Vaccines for SARS-CoV-2: lessons from other coronavirus strains. [Published erratum appears in 2021 Infect Dis. Ther. 10: 631.]","volume":"9","author":"Padron-Regalado","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"2025030417503669900_r133","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The challenges of vaccine development against a new virus during a pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell Host Microbe"},{"key":"2025030417503669900_r134","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.semdp.2019.04.006","article-title":"Emerging respiratory infections: the infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella","volume":"36","author":"Bradley","year":"2019","journal-title":"Semin. Diagn. Pathol."},{"key":"2025030417503669900_r135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fmicb.2020.00298","article-title":"Subunit vaccines against emerging pathogenic human coronaviruses","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Microbiol."},{"key":"2025030417503669900_r136","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"2025030417503669900_r137","doi-asserted-by":"crossref","first-page":"eabc8413","DOI":"10.1126\/sciimmunol.abc8413","article-title":"The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients","volume":"5","author":"Premkumar","year":"2020","journal-title":"Sci. Immunol."},{"key":"2025030417503669900_r138","doi-asserted-by":"crossref","first-page":"e1007236","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathog."},{"key":"2025030417503669900_r139","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"2025030417503669900_r140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"2025030417503669900_r141","doi-asserted-by":"crossref","first-page":"44875","DOI":"10.1038\/srep44875","article-title":"Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein","volume":"7","author":"Al-Amri","year":"2017","journal-title":"Sci. Rep."},{"key":"2025030417503669900_r142","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","article-title":"Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses","volume":"44","author":"Zhao","year":"2016","journal-title":"Immunity"},{"key":"2025030417503669900_r143","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12026-014-8534-z","article-title":"T cell-mediated immune response to respiratory coronaviruses","volume":"59","author":"Channappanavar","year":"2014","journal-title":"Immunol. Res."},{"key":"2025030417503669900_r144","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"2025030417503669900_r145","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"2025030417503669900_r146","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"2025030417503669900_r147","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2025030417503669900_r148","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r149","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"2025030417503669900_r150","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0140-6736(21)00191-4","article-title":"Sputnik V COVID-19 vaccine candidate appears safe and effective","volume":"397","author":"Jones","year":"2021","journal-title":"Lancet"},{"key":"2025030417503669900_r151","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r152","doi-asserted-by":"crossref","first-page":"JC15","DOI":"10.7326\/ACPJ202102160-015","article-title":"The BNT162b2 (BioNTech\/Pfizer) vaccine had 95% efficacy against COVID-19 \u22657 days after the 2nd dose","volume":"174","author":"Chagla","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"2025030417503669900_r153","first-page":"9","article-title":"FDA authorizes Moderna COVID-19 vaccine","volume":"63","year":"2021","journal-title":"Med. Lett. Drugs Ther."},{"key":"2025030417503669900_r154","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford-AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"2025030417503669900_r155","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r156","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat. Med."},{"key":"2025030417503669900_r157","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r158","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. [Published errata appear in 2020 Lancet 386: 466 and 2020 Lancet 396: 1884.]","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r159","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. [Published erratum appears in 2021 Nature 590: E17.]","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2025030417503669900_r160","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01330-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study","author":"Li","year":"2021","journal-title":"Nat. Med."},{"key":"2025030417503669900_r161","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"2025030417503669900_r162","article-title":"COVID-19 treatment and vaccine tracker","author":"Milken Institute","year":"2020"},{"key":"2025030417503669900_r163","article-title":"Pandemic and potentially pandemic influenza vaccines","author":"World Health Organization","year":"2020"},{"key":"2025030417503669900_r164","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01316-7","article-title":"Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine","author":"Levine-Tiefenbrun","year":"2021","journal-title":"Nat. Med."},{"key":"2025030417503669900_r165","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"2025030417503669900_r166","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"2025030417503669900_r167","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2912-6","article-title":"Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City","volume":"590","author":"Stadlbauer","year":"2021","journal-title":"Nature"},{"key":"2025030417503669900_r168","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat. Med."},{"key":"2025030417503669900_r169","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.18632\/aging.103344","article-title":"Why does COVID-19 disproportionately affect older people?","volume":"12","author":"Mueller","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2025030417503669900_r170","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","article-title":"Influence of immune aging on vaccine responses","volume":"145","author":"Gustafson","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"2025030417503669900_r171","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/21645515.2015.1062189","article-title":"Practical review of immunizations in adult patients with cancer","volume":"11","author":"Ariza-Heredia","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"2025030417503669900_r172","article-title":"Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis","author":"Akiyama","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"2025030417503669900_r173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun. Ageing"},{"key":"2025030417503669900_r174","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrrheum.2014.206","article-title":"Vaccination of patients with autoimmune inflammatory rheumatic diseases","volume":"11","author":"Westra","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"2025030417503669900_r175","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/S0140-6736(20)32318-7","article-title":"Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination","volume":"396","author":"Anderson","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r176","doi-asserted-by":"crossref","first-page":"583019","DOI":"10.3389\/fimmu.2020.583019","article-title":"Targeting inflammation and immunosenescence to improve vaccine responses in the elderly","volume":"11","author":"Pereira","year":"2020","journal-title":"Front. Immunol."},{"key":"2025030417503669900_r177","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30987-7","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","author":"Wu","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r178","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r179","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r180","doi-asserted-by":"crossref","first-page":"e2037640","DOI":"10.1001\/jamanetworkopen.2020.37640","article-title":"Assessment of the inclusion of racial\/ethnic minority, female, and older individuals in vaccine clinical trials","volume":"4","author":"Flores","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"2025030417503669900_r181","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.5084","article-title":"The exclusion of older persons from vaccine and treatment trials for coronavirus disease 2019-missing the target","author":"Helfand","year":"2020","journal-title":"JAMA Intern Med."},{"key":"2025030417503669900_r182","first-page":"136","article-title":"SARS-CoV-2 variant evades antibodies whilst maintaining fitness","volume":"21","author":"Flemming","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"2025030417503669900_r183","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab129","article-title":"Severe reinfection with South African SARS-CoV-2 variant 501Y.V2: A case report","author":"Zucman","year":"2021","journal-title":"Clin Infect Dis."},{"key":"2025030417503669900_r184","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","article-title":"Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant","volume":"183","author":"Yurkovetskiy","year":"2020","journal-title":"Cell"},{"key":"2025030417503669900_r185","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","article-title":"SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo","volume":"370","author":"Hou","year":"2020","journal-title":"Science"},{"key":"2025030417503669900_r186","doi-asserted-by":"crossref","first-page":"21617","DOI":"10.1038\/s41598-020-78703-6","article-title":"Genomic recombination events may reveal the evolution of coronavirus and the origin of SARS-CoV-2","volume":"10","author":"Zhu","year":"2020","journal-title":"Sci. Rep."},{"key":"2025030417503669900_r187","doi-asserted-by":"crossref","first-page":"eabb9153","DOI":"10.1126\/sciadv.abb9153","article-title":"Emergence of SARS-CoV-2 through recombination and strong purifying selection","volume":"6","author":"Li","year":"2020","journal-title":"Sci. Adv."},{"key":"2025030417503669900_r188","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/cid\/ciaa219","article-title":"2019 novel coronavirus is undergoing active recombination","volume":"71","author":"Yi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"2025030417503669900_r189","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1128\/JVI.01394-09","article-title":"Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission","volume":"84","author":"Graham","year":"2010","journal-title":"J. Virol."},{"key":"2025030417503669900_r190","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1056\/NEJMp2005630","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"382","author":"Lurie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r191","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nature04230","article-title":"Characterization of the 1918 influenza virus polymerase genes","volume":"437","author":"Taubenberger","year":"2005","journal-title":"Nature"},{"key":"2025030417503669900_r192","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMp058281","article-title":"The origins of pandemic influenza--lessons from the 1918 virus","volume":"353","author":"Belshe","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r193","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pathmechdis.3.121806.154316","article-title":"The pathology of influenza virus infections","volume":"3","author":"Taubenberger","year":"2008","journal-title":"Annu. Rev. Pathol."},{"key":"2025030417503669900_r194","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature08182","article-title":"Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic","volume":"459","author":"Smith","year":"2009","journal-title":"Nature"},{"key":"2025030417503669900_r195","article-title":"Adjuvants and vaccines","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2025030417503669900_r196","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"2025030417503669900_r197","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"key":"2025030417503669900_r198","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1073\/pnas.0804699105","article-title":"Molecular and cellular signatures of human vaccine adjuvants","volume":"105","author":"Mosca","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417503669900_r199","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J. Immunol."},{"key":"2025030417503669900_r200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"2025030417503669900_r201","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA as a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"2025030417503669900_r202","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"2025030417503669900_r203","doi-asserted-by":"crossref","first-page":"10704","DOI":"10.1128\/JVI.01166-12","article-title":"Entry of influenza A Virus with a \u03b12,6-linked sialic acid binding preference requires host fibronectin","volume":"86","author":"Leung","year":"2012","journal-title":"J. Virol."},{"key":"2025030417503669900_r204","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat. Med."},{"key":"2025030417503669900_r205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11481-020-09944-5","article-title":"The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections","volume":"15","author":"Machhi","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2025030417503669900_r206","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2353\/ajpath.2007.061088","article-title":"Pathology and pathogenesis of severe acute respiratory syndrome","volume":"170","author":"Gu","year":"2007","journal-title":"Am. J. Pathol."},{"key":"2025030417503669900_r207","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1165\/rcmb.2012-0339OC","article-title":"Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus","volume":"48","author":"Qian","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2025030417503669900_r208","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat. Mater."},{"key":"2025030417503669900_r209","first-page":"285","article-title":"Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada","volume":"169","author":"Varia","year":"2003","journal-title":"CMAJ"},{"key":"2025030417503669900_r210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3201\/eid1201.051370","article-title":"Non-pharmaceutical interventions for pandemic influenza, international measures","volume":"12","author":"Bell","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"2025030417503669900_r211","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/jcm9020462","article-title":"Estimation of the transmission risk of the 2019-nCoV and its implication for public health interventions","volume":"9","author":"Tang","year":"2020","journal-title":"J. Clin. Med."},{"key":"2025030417503669900_r212","first-page":"2000058","article-title":"Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. [Published erratum appears in 2020 Euro Surveill. DOI: 10.2807\/1560-7917.ES.2020.25.7.20200220c.]","volume":"25","author":"Riou","year":"2020","journal-title":"Eurosurveillance"},{"key":"2025030417503669900_r213","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","article-title":"Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics","volume":"20","author":"Petersen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r214","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(13)61504-4","article-title":"Assessing the pandemic potential of MERS-CoV","volume":"382","author":"Bauch","year":"2013","journal-title":"Lancet"},{"key":"2025030417503669900_r215","doi-asserted-by":"crossref","first-page":"105116","DOI":"10.1016\/j.earlhumdev.2020.105116","article-title":"Influenza vaccination in the COVID-19 era","volume":"148","author":"Grech","year":"2020","journal-title":"Early Hum. Dev."},{"key":"2025030417503669900_r216","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/jmv.25748","article-title":"Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures","volume":"92","author":"Wang","year":"2020","journal-title":"J. Med. Virol."},{"key":"2025030417503669900_r217","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccm.2016.11.007","article-title":"Epidemic and emerging coronaviruses (severe acute respiratory syndrome and Middle East respiratory syndrome)","volume":"38","author":"Hui","year":"2017","journal-title":"Clin. Chest Med."},{"key":"2025030417503669900_r218","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","article-title":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study","volume":"13","author":"Assiri","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"2025030417503669900_r219","article-title":"Q&A: influenza and COVID-19 - similarities and differences","author":"World Health Organization","year":"2020"},{"key":"2025030417503669900_r220","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/v10020093","article-title":"MERS-CoV: understanding the latest human coronavirus threat","volume":"10","author":"Chafekar","year":"2018","journal-title":"Viruses"},{"key":"2025030417503669900_r221","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.epidem.2015.04.003","article-title":"On the relative role of different age groups in influenza epidemics","volume":"13","author":"Worby","year":"2015","journal-title":"Epidemics"},{"key":"2025030417503669900_r222","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmi.2020.03.026","article-title":"COVID-19, SARS and MERS: are they closely related?","volume":"26","author":"Petrosillo","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"2025030417503669900_r223","article-title":"COVID-19, a worldwide public health emergency","author":"Palacios Cruz","year":"2020","journal-title":"Rev. Clin. Esp."},{"key":"2025030417503669900_r224","first-page":"4956","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics","volume":"22","author":"Nassar","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2025030417503669900_r225","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r226","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine - preliminary report","author":"Wu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r227","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.1375","article-title":"Necessity of 2 doses of the Pfizer and Moderna COVID-19 vaccines","author":"Livingston","year":"2021","journal-title":"JAMA."},{"key":"2025030417503669900_r228","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-020-03593-7","article-title":"Moderna COVID vaccine becomes second to get US authorization","author":"Ledford","year":"2020","journal-title":"Nature."},{"key":"2025030417503669900_r229","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. [Published erratum appears in 2021 Nature 590: E26.]","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"2025030417503669900_r230","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025030417503669900_r231","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"2025030417503669900_r232","doi-asserted-by":"crossref","first-page":"m4799","DOI":"10.1136\/bmj.m4799","article-title":"Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine","volume":"371","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"2025030417503669900_r233","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"2025030417503669900_r234","doi-asserted-by":"crossref","first-page":"n295","DOI":"10.1136\/bmj.n295","article-title":"Covid-19: AstraZeneca vaccine is approved in EU with no upper age limit","volume":"372","author":"Torjesen","year":"2021","journal-title":"BMJ"},{"key":"2025030417503669900_r235","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"2025030417503669900_r236","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/206\/11\/2509\/61368066\/ji2001287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/206\/11\/2509\/61368066\/ji2001287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T17:57:58Z","timestamp":1741111078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/206\/11\/2509\/7944654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":236,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.2001287","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6]]},"published":{"date-parts":[[2021,6,1]]}}}